NR4A1 and endometrial cancer: For patients with early endometrial cancer requiring fertility preservation and eligible for endocrine therapy, progesterone is the clinical first choice, and its therapeutic efficacy is highly related to the expression status of hormone receptors, especially the expression level of PR (13, 14).